{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T06:59:03Z","timestamp":1782543543529,"version":"3.54.5"},"reference-count":20,"publisher":"FapUNIFESP (SciELO)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:p>Lipodistrofia cong\u00eanita generalizada (CGL) com hipertrigliceridemia extrema desde o primeiro ano de vida est\u00e1 associada a piores riscos metab\u00f3licos. Foram utilizados dados contidos no prontu\u00e1rio do paciente, bem como revis\u00e3o bibliogr\u00e1fica para composi\u00e7\u00e3o do texto. Relatamos o caso de um lactente com fen\u00f3tipo t\u00edpico e hipertrigliceridemia de 1.360 mg\/dL, que foi tratado com bezafibrato na dose de 30 a 60 mg\/dia dos 11 meses aos 5 anos e 6 meses de idade, aferindo um nadir de triglic\u00e9rides de 55 mg\/dL. Evolu\u00e7\u00e3o cl\u00ednico-laboratorial antes e ap\u00f3s bezafibrato foi feita ao longo de cinco anos e seis meses. O fen\u00f3tipo apresentado foi classificado clinicamente em CGL tipo 2. Apesar do controle eficiente da hipetrigliceridemia e da aus\u00eancia de desenvolvimento de diabetes melito, o uso de bezafibrato n\u00e3o impediu o aparecimento de esteatose hep\u00e1tica durante a evolu\u00e7\u00e3o. A terapia antilipemiante com fibrato se mostrou eficaz em manter n\u00edveis normais de triglicer\u00eddeos, colesterol e suas fra\u00e7\u00f5es e n\u00e3o se associou a efeitos colaterais graves durante o per\u00edodo descrito.<\/jats:p>","DOI":"10.1590\/s0004-27302013000800012","type":"journal-article","created":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T13:32:28Z","timestamp":1387027948000},"page":"653-658","source":"Crossref","is-referenced-by-count":1,"title":["Bezafibrato em lactente portador de lipodistrofia generalizada cong\u00eanita e hipertrigliceridemia grave"],"prefix":"10.1590","volume":"57","author":[{"given":"Rog\u00e9rio Santiago","family":"Ara\u00fajo","sequence":"first","affiliation":[{"name":"Universidade Estadual do Piau\u00ed,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 de Paula Silva","family":"Ramos","sequence":"additional","affiliation":[{"name":"Universidade Estadual do Piau\u00ed,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1riton de Ara\u00fajo Sousa","family":"Borges","sequence":"additional","affiliation":[{"name":"Universidade Estadual do Piau\u00ed,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0002-9343(99)00414-3","article-title":"Lipodystrophies","volume":"108","author":"Garg A","year":"2000","journal-title":"Am J Med."},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Medical progress: acquired and inherited lipodystrophies","volume":"350","author":"Garg A","year":"2004","journal-title":"N Engl J Med."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ecl.2004.03.003","article-title":"Lipodystrophies: rare disorders causing metabolic syndrome","volume":"33","author":"Garg A","year":"2004","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review#: Lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg AJ","year":"2011","journal-title":"Clin Endocrinol Metab."},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","article-title":"Serum adiponectin and leptin levels in patients with lipodystrophies","volume":"87","author":"Haque WA","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00004836-200301000-00016","article-title":"Issues in hyperlipidemic pancreatitis","volume":"36","author":"Yadav D","year":"2003","journal-title":"J Clin Gastroenterol."},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0b013e32832d4a33","article-title":"Inherited lipodystrophies and hypertriglyceridemia","volume":"20","author":"Simha V","year":"2009","journal-title":"Curr Opin Lipidol."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1210\/jc.2003-030835","article-title":"Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy due to mutations in the AGPAT2 or Seipin genes","volume":"88","author":"Simha V","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/ajmg.a.32457","article-title":"Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability","volume":"146A","author":"Simha V","year":"2008","journal-title":"Am J Med Genet A."},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0b013e32832d4a33","article-title":"Inherited lipodystrophies and hypertriglyceridemia","volume":"20","author":"Simha V","year":"2009","journal-title":"Curr Opin Lipidol."},{"issue":"Suppl 1","key":"ref11","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.4103\/2230-8210.83054","article-title":"Berardinelli Seip syndrome with insulin-resistant diabetes mellitus and stroke in an infant","volume":"15","author":"Indumathi CK","year":"2011","journal-title":"Indian J Endocrinol Metab."},{"issue":"14","key":"ref12","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1161\/CIRCULATIONAHA.107.181946","article-title":"Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing","volume":"115","author":"McCrindle BW","year":"2007","journal-title":"Circulation."},{"issue":"1","key":"ref13","first-page":"6","article-title":"Preven\u00e7\u00e3o da aterosclerose e tratamento medicamentoso de anormalidades lip\u00eddicas de alto risco em crian\u00e7as e adolescentes","volume":"85","author":"Castro PSG","year":"2009","journal-title":"J Pediatr (Rio J)."},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan G","year":"2007","journal-title":"CMAJ."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"28210","DOI":"10.1074\/jbc.272.45.28210","article-title":"Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl CoA synthetase (ACS) genes by PPARa and PPARg activators","volume":"272","author":"Martin G","year":"1997","journal-title":"J Biol Chem."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.1996.03530250059028","article-title":"Carcinogenicity of lipid-lowering drugs","volume":"275","author":"Newman T","year":"1996","journal-title":"JAMA."},{"key":"ref17","first-page":"351","article-title":"Side effects of fibrates (except liver and muscle)","volume":"46","author":"Sgro C","year":"1991","journal-title":"Therapie."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CRD.0b013e31816b43d3","article-title":"Fibrate therapy: an update","volume":"16","author":"Remick J","year":"2008","journal-title":"Cardiol Rev."},{"key":"ref19","first-page":"47","article-title":"Severe gastrointestinal bleeding induced by a probable hydroxycoumarin-bezafibrate interaction","volume":"28","author":"Blum A","year":"1992","journal-title":"Isr J Med Sci."},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/adc.60.1.34","article-title":"Double blind trial of bezafibrate in familial hypercholesterolaemia","volume":"60","author":"Wheeler KA","year":"1985","journal-title":"Arch Dis Child."}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v57n8\/12.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T17:17:19Z","timestamp":1495905439000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302013000800012&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0004-27302013000800012"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302013000800012","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}